Switch to:
Also traded in: Israel, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
BOLT's Cash to Debt is ranked higher than
84% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. BOLT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BOLT' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.80
BOLT's Equity to Asset is ranked higher than
64% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BOLT: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
BOLT' s Equity to Asset Range Over the Past 10 Years
Min: 0.69  Med: 0.71 Max: 0.8
Current: 0.8
0.69
0.8
Z-Score: -7.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1679.85
BOLT's Operating margin (%) is ranked lower than
81% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. BOLT: -1679.85 )
Ranked among companies with meaningful Operating margin (%) only.
BOLT' s Operating margin (%) Range Over the Past 10 Years
Min: -55473.08  Med: -34685.37 Max: -1679.85
Current: -1679.85
-55473.08
-1679.85
Net-margin (%) -1189.42
BOLT's Net-margin (%) is ranked lower than
78% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. BOLT: -1189.42 )
Ranked among companies with meaningful Net-margin (%) only.
BOLT' s Net-margin (%) Range Over the Past 10 Years
Min: -25684.62  Med: -22971.95 Max: -1189.42
Current: -1189.42
-25684.62
-1189.42
ROE (%) -58.11
BOLT's ROE (%) is ranked lower than
65% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. BOLT: -58.11 )
Ranked among companies with meaningful ROE (%) only.
BOLT' s ROE (%) Range Over the Past 10 Years
Min: -299.64  Med: -206.2 Max: -58.11
Current: -58.11
-299.64
-58.11
ROA (%) -43.17
BOLT's ROA (%) is ranked lower than
64% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. BOLT: -43.17 )
Ranked among companies with meaningful ROA (%) only.
BOLT' s ROA (%) Range Over the Past 10 Years
Min: -109.73  Med: -85.77 Max: -43.17
Current: -43.17
-109.73
-43.17
ROC (Joel Greenblatt) (%) -339.65
BOLT's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. BOLT: -339.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BOLT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6244.13  Med: -3742.79 Max: -339.65
Current: -339.65
-6244.13
-339.65
» BOLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

BOLT Guru Trades in

Q2 2014

BOLT Guru Trades in Q2 2014

Jim Simons 215,145 sh (+7.68%)
John Rogers 552,106 sh (-0.05%)
» More
Q3 2014

BOLT Guru Trades in Q3 2014

Mario Gabelli 134,748 sh (New)
John Rogers Sold Out
Jim Simons 171,700 sh (-20.19%)
» More
Q4 2014

BOLT Guru Trades in Q4 2014

Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BOLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CASC, NAS:VTL, AMEX:PIP, NAS:RDHL, NAS:CYAD, OTCPK:SPHRY, NAS:EGLT, NAS:ARGS, NAS:RGLS, NAS:CARA, NAS:KMDA, OTCPK:MXDHF, NAS:MRUS, NAS:STML, NAS:QURE, NAS:PRQR, NAS:OCUL, NAS:MDWD, AMEX:MDGN, NAS:FLKS » details
Traded in other countries:BOLT.Israel, BLGTY.USA,
BioLight Life Sciences Ltd is engaged in discovery, development and commercialization of products and product candidates with opthalmic conditions, including dry eye syndrome and age related macular degeneration.

BioLight Life Sciences Ltd was incorporated in Israel on April 20, 2005. It is an emerging ophthalmic company, focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, DES and AMD. Its products and product candidates are designed to address a number of unmet medical needs of large and growing patient populations related to ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering diagnosis and optimizing delivery of medications.

Ratios

vs
industry
vs
history
P/B 0.92
BOLT's P/B is ranked higher than
94% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. BOLT: 0.92 )
Ranked among companies with meaningful P/B only.
BOLT' s P/B Range Over the Past 10 Years
Min: 0.92  Med: 2.39 Max: 3.37
Current: 0.92
0.92
3.37
P/S 17.35
BOLT's P/S is ranked lower than
59% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. BOLT: 17.35 )
Ranked among companies with meaningful P/S only.
BOLT' s P/S Range Over the Past 10 Years
Min: 17.35  Med: 78.77 Max: 613.64
Current: 17.35
17.35
613.64
EV-to-EBIT 1.99
BOLT's EV-to-EBIT is ranked higher than
87% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. BOLT: 1.99 )
Ranked among companies with meaningful EV-to-EBIT only.
BOLT' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.6  Med: -1.8 Max: 1.99
Current: 1.99
-4.6
1.99
EV-to-EBITDA 2.12
BOLT's EV-to-EBITDA is ranked higher than
88% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. BOLT: 2.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
BOLT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.7  Med: -2 Max: 2.12
Current: 2.12
-5.7
2.12
Current Ratio 7.09
BOLT's Current Ratio is ranked higher than
65% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. BOLT: 7.09 )
Ranked among companies with meaningful Current Ratio only.
BOLT' s Current Ratio Range Over the Past 10 Years
Min: 4.95  Med: 7.07 Max: 8.05
Current: 7.09
4.95
8.05
Quick Ratio 6.91
BOLT's Quick Ratio is ranked higher than
66% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. BOLT: 6.91 )
Ranked among companies with meaningful Quick Ratio only.
BOLT' s Quick Ratio Range Over the Past 10 Years
Min: 4.8  Med: 6.91 Max: 7.86
Current: 6.91
4.8
7.86
Days Inventory 403.68
BOLT's Days Inventory is ranked lower than
92% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. BOLT: 403.68 )
Ranked among companies with meaningful Days Inventory only.
BOLT' s Days Inventory Range Over the Past 10 Years
Min: 403.68  Med: 4530.08 Max: 8371.2
Current: 403.68
403.68
8371.2
Days Sales Outstanding 118.57
BOLT's Days Sales Outstanding is ranked lower than
79% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. BOLT: 118.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
BOLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 113.26  Med: 163.46 Max: 213.66
Current: 118.57
113.26
213.66
Days Payable 417.92
BOLT's Days Payable is ranked higher than
92% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. BOLT: 417.92 )
Ranked among companies with meaningful Days Payable only.
BOLT' s Days Payable Range Over the Past 10 Years
Min: 417.92  Med: 11150.87 Max: 21661.96
Current: 417.92
417.92
21661.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.64
BOLT's Dividend Yield is ranked higher than
62% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. BOLT: 1.64 )
Ranked among companies with meaningful Dividend Yield only.
BOLT' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.64
Current: 1.64
0
1.64
Dividend Payout 0.60
BOLT's Dividend Payout is ranked lower than
77% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. BOLT: 0.60 )
Ranked among companies with meaningful Dividend Payout only.
BOLT' s Dividend Payout Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.6
Current: 0.6
0
0.6
Yield on cost (5-Year) 1.64
BOLT's Yield on cost (5-Year) is ranked higher than
54% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 1.44 vs. BOLT: 1.64 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BOLT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.64
Current: 1.64
0
1.64

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.30
BOLT's Price/Net Cash is ranked higher than
94% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. BOLT: 1.30 )
Ranked among companies with meaningful Price/Net Cash only.
BOLT' s Price/Net Cash Range Over the Past 10 Years
Min: 1.3  Med: 7.08 Max: 48.53
Current: 1.3
1.3
48.53
Price/Net Current Asset Value 1.16
BOLT's Price/Net Current Asset Value is ranked higher than
95% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. BOLT: 1.16 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BOLT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.16  Med: 3.09 Max: 3.53
Current: 1.16
1.16
3.53
Price/Tangible Book 1.12
BOLT's Price/Tangible Book is ranked higher than
94% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. BOLT: 1.12 )
Ranked among companies with meaningful Price/Tangible Book only.
BOLT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.12  Med: 2.96 Max: 3.38
Current: 1.12
1.12
3.38
Price/Median PS Value 0.22
BOLT's Price/Median PS Value is ranked higher than
93% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. BOLT: 0.22 )
Ranked among companies with meaningful Price/Median PS Value only.
BOLT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.03 Max: 5.4
Current: 0.22
0.22
5.4
Earnings Yield (Greenblatt) (%) 50.30
BOLT's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. BOLT: 50.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BOLT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 50.3
Current: 50.3
0
50.3

More Statistics

Revenue (TTM) (Mil) $0.47
EPS (TTM) $ -0.10
Short Percentage of Float0.55%
52-Week Range $15.94 - 22.76
Shares Outstanding (Mil)8.71
» More Articles for BOLT

Headlines

Articles On GuruFocus.com

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)